Audit: QRS - Methylene Blue for Health & Longevity

Audit conducted on 11/05/2026 10:05 using AI4L / Opus 5.5

Iterations

Summary

Items	Count
Total	97
Passed	87
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Lede, Protocol, Time to effect, Benefits, Risks, gates, Monitoring and Qualitative items each trace to ER text (Conclusion, Therapeutic Protocol, Practical Considerations, Expected Benefits, Potential Risks, Key Interactions & Contraindications, Monitoring Protocol).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Hedges kept: “no longevity regimen tested”, “Common practice”, “no study has examined sleep effects”, “Measured after a single dose”, “judged not clinically relevant”, “No established target”, theoretical items keep “Could”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	No strengthening or softening found; contraindications stay contraindications, cautious time-to-effect wording kept.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come from the ER’s avoid list, interactions from the documented/theoretical groups, monitoring from the Monitoring Protocol; no modifying factor relabeled.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, study names, expert names or brand names (e.g., ProvayBlue) appear on the sheet.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s measured, evidence-weighted tone.
2.2	The tone of the QRS is expert, accessible, objective, and data-driven	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢	“Avoid” in the interaction gate is the ER’s own decision-gate wording; no clinical advice added.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses the reader directly — it presents evidence, not guidance	🟢	No second-person address found.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms (e.g., UGT1A4, PDE5, myoclonus, thiazine dyes) are part of ER labels carried verbatim.
2.8	Information is presented in a concise and very compact manner	🟢
2.9	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.10	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.11	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Lede states the strongest evidence lies outside longevity and aging claims rest on cell and animal work.
2.13	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No “anti-aging” in the sheet’s voice.
2.14	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	No pill/shot/by-mouth phrasing; route terms are “intravenous”.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and column headers unchanged.
3.2	Every element carrying a data-qrs-var attribute in [qrs_template] is present in the QRS with the same name	🟢	All template data-qrs-var names present; # patterns expanded to marker_1..9 and qualitative_item_1..5.
3.3	Everything outside the data-qrs-var spans — markup, text, styles, comments — is as in the template; spans that no checklist item addresses are left unchanged as well	🟢	Diff vs template: only metadata values (plus workflow git/duration keys), the allowed display:none on benefits_medium and the unused time_3 cell, and expanded # rows.

4. Formatting

#	Description	Result	Comments
4.1	An empty ER section never produces visible empty-state text in the QRS: the corresponding region is hidden or left empty. Phrases such as “None documented in human trials to date” or “Not formally studied” appear only where the ER uses them for a fact the QRS carries over.	🟢	Empty Medium benefit tier hidden; only “Not specified in the ER” (AST target) appears, as 14.3 prescribes.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels (“Daily cognition approach”, “Daily mood approach”, “Time of day”), interaction labels and qualitative labels use the ER’s bold labels.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Interaction labels trimmed only by dropping glosses and example names; kept words are the ER’s own.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji in the QRS.
4.5	The QRS is designed to render on one A4 page. It fails this item only for one of four things: a trailing clause after a dash, an optional gloss, an example list left untrimmed, or a repetition. Nothing else is cut to fit.	🟢	No trailing dash clause, optional gloss, untrimmed example list or repetition found.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration is quoted (contains a colon).
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	26.10.25 matches QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	2026-1105-0911
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is the full name without the version number, with all remaining words joined by hyphens (e.g., Opus, Sonnet, Grok, Gemini-Flash, GPT); when the full name has no version number or is “Unknown”, the nickname equals the full name	🟢	Opus
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the model name (the word or words directly before the version number, leaving out the first if there is more than one, e.g., Claude Opus 5.5 → Opus 5.5), the model version number and the variant (if any) as stated in the system prompt or developer instructions of the creating model, with every word capitalized and without product, effort or pricing names (e.g., Opus X.Y, Sonnet X.Y, Grok X.Y, Gemini X.Y Flash, GPT X.Y), the model name alone when the system prompt or developer instructions name a model without a version number (e.g., Grok), or “Unknown” when neither the system prompt nor the developer instructions of the creating model name a model	🟢	Opus 5.5
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	11/05/2026
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens “an old dye turned medicine, is taken for brain health and healthy aging”.
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the Conclusion’s evidence pattern and key risks.
7.3	[at_a_glance] is no longer than 70 words	🟢	69 words.
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Motivation (brain health/healthy aging use) and Conclusion paragraphs 1-3 support each fact.
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven ER avoid-list populations present.
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Breastfeeding window (up to 8 days) and eGFR 15–59 threshold kept.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER uses no ranking notation.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	Section populated; ER names populations to avoid.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the ER’s documented interactions — the items under its “Documented interactions:” label — excluding any that are already listed as Contraindications and any entry phrased as no interaction found	🟢	Seven documented interactions; the no-interaction midazolam/caffeine/warfarin entry excluded. The drug-class items specify the members and 72-hour window behind the broader “People taking serotonergic drugs or opioids” contraindication rather than duplicating an item.
9.3	[caution_theoretical_items] represent the ER’s theoretical interactions — the items under its “Theoretical interactions (inferred from mechanism, not studied in humans):” label	🟢	All six theoretical interactions present.
9.4	The ER placeholder “None identified” is never an item: it means that group is empty	🟢
9.5	Individual [caution_items] and [caution_theoretical_items] are formatted as <li></li>. The template’s bold “Theoretical (inferred from mechanism)” sub-heading is the only marker of the second list’s status: no item carries “(theoretical)”, “inferred from” or a mechanism clause	🟢	No item carries “(theoretical)” or a mechanism clause.
9.6	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.7	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists kept (trimmed) and 72-hour windows preserved.
9.8	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER uses no ranking notation.
9.9	If the ER’s theoretical group is empty, the whole Theoretical block — the caution_theoretical span with its sub-heading and list — is hidden with style="display:none", not removed: its spans stay in place, empty.	N/A	ER’s theoretical group is not empty.
9.10	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	Section populated.
9.11	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on, and the Theoretical block is hidden per 9.9. E.g.	N/A	Section not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Therapeutic Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from that section	🟢	Daily cognition dose, daily mood dose and time of day.
10.3	If fewer than three distinct actionable implementation aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing.	N/A	ER names more than three actionable aspects.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from that section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	ER gives two time-to-effect aspects (Practical Considerations); both used.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Mood in bipolar disorder (High benefit) precedes brain activity and memory (Low).
11.3	If fewer than three distinct time-to-effect aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing.	🟢	Third set left empty and hidden with display:none.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER provides no information on time to effect at all, the whole Time to effect block (its subhead and all three sets) is hidden with style="display:none", not removed: its spans stay in place, empty.	N/A	ER provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are the ER benefit headings without magnitudes.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content.
12.5	If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	Empty Medium tier hidden with display:none.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are the ER risk headings without frequencies.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content.
13.5	If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers have items.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring Protocol & Defining Success section	🟢
14.2	All measurable/quantifiable biomarkers from that section are listed, one table row per marker; the template’s # row is the pattern, repeated with # replaced by 1, 2, 3 … in the data-qrs-var names	🟢	Nine rows: G6PD, hemoglobin, indirect bilirubin, haptoglobin, eGFR, ALT, AST, methemoglobin, blood pressure.
14.3	[marker_#name] is the marker, [marker#target] its target value or range as given in the ER, [marker#_why] its purpose in a few words; a target the ER does not give is written “Not specified in the ER”	🟢	Targets match the ER table; AST target “Not specified in the ER”.
14.4	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from that section. It is not left with placeholder text or empty.	🟢
14.5	If the ER names no measurable biomarker, the table is hidden with style="display:none" and the single # row is left as in the template	N/A	ER names measurable biomarkers.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring Protocol & Defining Success section	🟢
15.2	All subjective/qualitative markers from that section are listed, one <li> per marker; the template’s # item is the pattern, repeated with # replaced by 1, 2, 3 …	🟢	All five ER qualitative markers listed verbatim.
15.3	If the ER names no qualitative marker, the card’s list is hidden with style="display:none" and the single # item is left as in the template	N/A	ER names qualitative markers.

Issues 11/05/2026 10:05

Pass rate 100.00%. No issues found.

Issues 11/05/2026 10:01

1. 14.2 — Two markers in one row: Line 647–653 combines “Indirect bilirubin and haptoglobin” into a single row (marker_3) with two separate targets, instead of one table row per marker.

Fixes 11/05/2026 10:01

1. 14.2 — Two markers in one row: Split the “Indirect bilirubin and haptoglobin” row into separate rows “Indirect bilirubin” (0.2–0.8 mg/dL, “A rise signals hemolysis”) and “Haptoglobin” (30–200 mg/dL, “A fall signals hemolysis”); renumbered the following markers 5–9.

Issues 11/05/2026 09:57

1. 2.14 — Colloquial verb in lede: At a Glance (line 439) says methylene blue “can react dangerously with common antidepressants”; the formal clinical term for a drug-drug effect is “interact”.

Fixes 11/05/2026 09:57

1. 2.14 — Colloquial verb in lede: Changed “can react dangerously with common antidepressants” to “can interact dangerously with common antidepressants” in At a Glance.

Issues 11/05/2026 09:53

1. 1.1 — MAO inhibitor list misgrouped: The Key Interactions item at line 563 trims “phenelzine and tranylcypromine” to “phenelzine”, so “(MAO inhibitors such as phenelzine, clomipramine, bupropion, linezolid)” presents clomipramine and bupropion as MAO inhibitors, which the ER (line 376) does not say.

Fixes 11/05/2026 09:53

1. 1.1 — MAO inhibitor list misgrouped: Restored “phenelzine and tranylcypromine” in the Other serotonergic drugs label so clomipramine, bupropion and linezolid no longer read as MAO inhibitor examples, matching the ER grouping.

Issues 11/05/2026 09:49

1. 4.5 — Example lists left untrimmed: The Photosensitizing item (line 583) keeps all three ER examples “(doxycycline, isotretinoin, red or near-infrared light)” and the Triptans item (line 568) keeps both “(sumatriptan, rizatriptan)”; the Other serotonergic drugs item (line 563) keeps two MAO inhibitor examples “phenelzine and tranylcypromine”.

Fixes 11/05/2026 09:49

1. 4.5 — Trimmed interaction example lists: Cut the examples to “(doxycycline, red or near-infrared light)” in the Photosensitizing item, “(sumatriptan)” in the Triptans item, and “MAO inhibitors such as phenelzine” in the Other serotonergic drugs item.

Issues 11/05/2026 09:43

1. 7.2 — Lede omits mood finding: The at_a_glance text at line 439 summarizes the Conclusion but leaves out its bipolar-depression finding from two independent groups (and the pregnancy harm), so it is not a complete summary of the ER Conclusion.

Fixes 11/05/2026 09:43

1. 7.2 — Lede omits mood finding: Rewrote at_a_glance (69 words) to add “Small trials eased bipolar depression” and “may harm a developing baby” from the ER Conclusion, tightening the other clauses to stay within 70 words.

Issues 11/05/2026 09:40

1. 4.5 — Untrimmed example lists, repetition: The Opioids (line 564), Serotonergic supplements (line 578), Oxidant drugs (line 580), Tyramine-rich foods (line 579) and Nitrates and PDE5 inhibitors (line 581) items carry the ER’s full example lists in an over-dense sheet; the AST “Why” cell (line 686) repeats ALT’s “liver injury changes use” (line 675).

Fixes 11/05/2026 09:40

1. 4.5 — Trimmed example lists, removed repetition: Trimmed example lists to Opioids (tramadol, meperidine, fentanyl), Serotonergic supplements (St John’s wort, 5-HTP, L-tryptophan), Tyramine-rich foods (aged cheese, cured meats), Oxidant drugs (dapsone, primaquine, nitrofurantoin) and Nitrates and PDE5 inhibitors (nitroglycerin, sildenafil); shortened the AST “Why” cell from “Pairs with ALT; liver injury changes use” to “Pairs with ALT”.

Issues 11/05/2026 09:36

1. 1.3 — Measurement time as onset: The time_2 cell (lines 500-506) shows “1 hour” / “After a single dose” as the time to effect, while the ER (line 463) says brain-activity and memory changes “were measured one hour after a single dose”.

Fixes 11/05/2026 09:36

1. 1.3 — Measurement time as onset: Changed time_2_sub from “After a single dose” to “Measured after a single dose”, matching the ER wording that changes were measured one hour after a single dose.

Issues 11/05/2026 09:30

1. 1.1 — Dose-drug pairing lost: Protocol action_2 (lines 464, 467) gives “195 or 300 mg/day” with “Added to lamotrigine or lithium in bipolar disorder”, dropping the ER pairing of 195 mg/day with lamotrigine and 300 mg/day with lithium.
2. 4.5 — Time-to-effect subs repeat values: time_1_sub “Mood changes emerged within 3-month treatment periods” restates “Within 3 months” (lines 492, 495), and time_2_sub “Changes measured one hour after a single dose” restates “1 hour” (lines 503, 506).

Fixes 11/05/2026 09:30

1. 1.1 — Dose-drug pairing restored: Changed action_2_sub from “Added to lamotrigine or lithium in bipolar disorder” to “Added to lamotrigine or lithium, respectively, in bipolar disorder”, matching the ER’s 195 mg/day–lamotrigine and 300 mg/day–lithium pairing.
2. 4.5 — Time-to-effect repetition removed: Changed time_1_sub to “Emerged within the trial treatment periods” and time_2_sub to “After a single dose” so neither restates its value.

Issues 11/05/2026 09:28

1. 4.5 — Optional gloss in AST row: The AST Why cell at line 686 reads “Pairs with ALT; leaks when liver cells are damaged”, an optional gloss of what AST is rather than its purpose.

Fixes 11/05/2026 09:28

1. 4.5 — Optional gloss in AST row: Replaced marker_6_why “Pairs with ALT; leaks when liver cells are damaged” with “Pairs with ALT; liver injury changes use”, following the ER’s ALT purpose.

Issues 11/05/2026 09:24

1. 1.1 — MAO inhibitor example misgrouped: The Key Interactions label at line 563 reads “MAO inhibitors such as phenelzine, clomipramine, bupropion, linezolid”, dropping “and tranylcypromine” so clomipramine and bupropion appear to be MAO inhibitors; the ER lists “MAO inhibitors such as phenelzine and tranylcypromine” as one example and clomipramine and bupropion as separate agents.

Fixes 11/05/2026 09:24

1. 1.1 — MAO inhibitor example misgrouped: Restored “and tranylcypromine” in the Other serotonergic drugs label, so it now reads “MAO inhibitors such as phenelzine and tranylcypromine, clomipramine, bupropion, linezolid” as in the ER.

Issues 11/05/2026 09:22

1. 4.5 — Untrimmed interaction example lists: Line 562 keeps all five SSRI/SNRI examples and line 563 all seven “Other serotonergic drugs” examples (including “phenelzine and tranylcypromine”) on an already crowded sheet.

Fixes 11/05/2026 09:22

1. 4.5 — Trimmed interaction example lists: Shortened the SSRI/SNRI examples to “sertraline, fluoxetine, venlafaxine” and the “Other serotonergic drugs” examples to “MAO inhibitors such as phenelzine, clomipramine, bupropion, linezolid”, keeping the ER’s own words.

Issues 11/05/2026 09:19

1. 14.2 — AST marker missing: The ER Monitoring table (line 492) names AST (“pair with AST (aspartate aminotransferase…)”) as a measured liver marker, but the QRS Monitoring table (lines 614-701) lists no AST row.

Fixes 11/05/2026 09:19

1. 14.2 — AST marker added: Added an AST row (target “Not specified in the ER”, why “Pairs with ALT; leaks when liver cells are damaged”) after ALT and renumbered the methemoglobin and blood pressure rows to marker_7 and marker_8.

Issues 11/05/2026 09:14

1. 1.1 — MAO-inhibitor examples misgrouped: The Key Interactions label at line 563 reads “MAO inhibitors such as phenelzine, clomipramine, bupropion, buspirone, mirtazapine, linezolid”, presenting non-MAOI drugs as MAO-inhibitor examples; the ER reads “MAO inhibitors such as phenelzine and tranylcypromine, clomipramine, bupropion, …”.
2. 4.3 — Benefit heading paraphrased: The Low benefit at line 534 reads “add-on to periodontitis treatment” instead of the ER heading “Adjunct to Periodontitis Treatment”.
3. 11.1 / 11.3 — Unsupported third time-to-effect set: Set 2 at lines 500–506 (“Blood pressure in septic shock / 6 hours”) reuses a measurement time point from a Risks magnitude (Fernando 2024), not an ER time-to-effect statement; the ER names only two time-to-effect aspects, so the unused set should be empty and hidden.

Fixes 11/05/2026 09:14

1. 1.1 — MAO-inhibitor examples restored: Changed “MAO inhibitors such as phenelzine, clomipramine, …” to the ER’s “MAO inhibitors such as phenelzine and tranylcypromine, clomipramine, …” so only true MAO inhibitors are grouped under that phrase.
2. 4.3 — Benefit heading restored: Replaced “add-on to periodontitis treatment” with the ER heading wording “adjunct to periodontitis treatment”.
3. 11.1 / 11.3 — Third time-to-effect set removed: Dropped the “Blood pressure in septic shock / 6 hours” set, moved “Brain activity and memory / 1 hour” into set 2, and left set 3 empty and hidden with style=”display:none”.